|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:2014
gptkb:2018
gptkb:2020
Heraeus Medical
Thrombo Genics
|
|
gptkbp:ceo
|
Manuel L. Morán
|
|
gptkbp:clinical_trial
|
ongoing
investing in R& D
|
|
gptkbp:collaborations
|
academic institutions
biotech companies
|
|
gptkbp:employees
|
approximately 1,500
|
|
gptkbp:founded
|
1943
|
|
gptkbp:founder
|
Alfredo Almirall
|
|
gptkbp:global_presence
|
over 70 countries
|
|
gptkbp:headcount
|
1,500 (2021)
|
|
gptkbp:headquarters
|
gptkb:Barcelona
gptkb:Barcelona,_Spain
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Almirall
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
numerous
|
|
gptkbp:market
|
global
|
|
gptkbp:partnership
|
gptkb:temple
gptkb:Abb_Vie
|
|
gptkbp:products
|
respiratory treatments
dermatology treatments
|
|
gptkbp:research_areas
|
dermatology
pain management
respiratory
|
|
gptkbp:research_focus
|
skin diseases
chronic obstructive pulmonary disease
|
|
gptkbp:revenue
|
€1.1 billion (2020)
|
|
gptkbp:subsidiary
|
Almirall LLC
Almirall Prodesfarma
|
|
gptkbp:sustainability_initiatives
|
gptkb:government_agency
social responsibility
environmental responsibility
|
|
gptkbp:symbol
|
ALM
|
|
gptkbp:website
|
www.almirall.com
|
|
gptkbp:bfsParent
|
gptkb:IBEX_35_index
gptkb:Madrid_Stock_Exchange
|
|
gptkbp:bfsLayer
|
5
|